Detalhe da pesquisa
1.
Chimpanzee Adenovirus Vector Ebola Vaccine.
N Engl J Med
; 376(10): 928-938, 2017 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-25426834
2.
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.
Lancet
; 391(10120): 552-562, 2018 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29217376
3.
A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.
N Engl J Med
; 374(17): 1635-46, 2016 Apr 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-25629663
4.
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.
PLoS Med
; 15(1): e1002493, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29364886
5.
Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design.
J Virol
; 90(13): 5899-5914, 2016 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27053554
6.
Development of high-throughput and high sensitivity capillary gel electrophoresis platform method for Western, Eastern, and Venezuelan equine encephalitis (WEVEE) virus like particles (VLPs) purity determination and characterization.
Electrophoresis
; 38(20): 2610-2621, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28842921
7.
Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial.
Lancet
; 384(9959): 2046-52, 2014 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-25132507
8.
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial.
Nat Med
; 28(5): 1022-1030, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35411076
9.
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial.
Lancet Respir Med
; 9(10): 1111-1120, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33864736
10.
Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity.
J Virol
; 83(14): 7166-75, 2009 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-19420074
11.
A proof of concept for structure-based vaccine design targeting RSV in humans.
Science
; 365(6452): 505-509, 2019 08 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31371616
12.
Structural Characterization and Formulation Development of a Trivalent Equine Encephalitis Virus-Like Particle Vaccine Candidate.
J Pharm Sci
; 107(10): 2544-2558, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29883665
13.
An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial.
NPJ Vaccines
; 2: 15, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29263871
14.
Characterization of N-glycosylation profiles from mammalian and insect cell derived chikungunya VLP.
J Chromatogr B Analyt Technol Biomed Life Sci
; 1032: 218-223, 2016 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27157808
15.
A Micro-Polyethylene Glycol Precipitation Assay as a Relative Solubility Screening Tool for Monoclonal Antibody Design and Formulation Development.
J Pharm Sci
; 105(8): 2319-27, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27368120
16.
Phase 1 study of pandemic H1 DNA vaccine in healthy adults.
PLoS One
; 10(4): e0123969, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25884189
17.
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection.
Sci Transl Med
; 7(319): 319ra206, 2015 12 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-26702094
18.
Development and application of a reversed-phase high-performance liquid chromatographic method for quantitation and characterization of a Chikungunya virus-like particle vaccine.
J Chromatogr A
; 1364: 192-7, 2014 Oct 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-25234500
19.
Development of a stable virus-like particle vaccine formulation against Chikungunya virus and investigation of the effects of polyanions.
J Pharm Sci
; 102(12): 4305-14, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24129946
20.
Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination.
PLoS One
; 7(4): e33969, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22496775